Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000814115 | SCV000954515 | pathogenic | Greig cephalopolysyndactyly syndrome; Pallister-Hall syndrome | 2018-12-27 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the GLI3 protein. Other variant(s) that disrupt this region (p.Thr1488Lysfs*23) have been determined to be pathogenic (PMID: 24736735). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. Experimental studies and prediction algorithms are not available for this variant, and the functional significance of the affected amino acid(s) is currently unknown. This variant has not been reported in the literature in individuals with GLI3-related conditions. ClinVar contains an entry for this variant (Variation ID: 38326). This sequence change results in a premature translational stop signal in the GLI3 gene (p.Gln1161*). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 420 amino acids of the GLI3 protein. |